Hypomagnesemia and mild rhabdomyolysis in living related donor renal transplant recipient treated with cyclosporine A

Scand J Urol Nephrol. 1998 Dec;32(6):415-7. doi: 10.1080/003655998750015223.

Abstract

Since cyclosporine A (CsA) had been used in renal transplant recipients, important improvements in short-term and long-term graft survivals have been detected. In spite of these improvements CsA seems to have several adverse effects. First, CsA leads to nephrotoxicity. Moreover, CsA affects the other organs and systems (skin, liver, nervous system, etc.) and causes, increased risks of infections and malignancies. Hypomagnesemia is one of the side effects of CsA therapy, but it is a rare condition in living related donor renal transplant recipients. It may also cause multi-system dysfunction, especially hypocalcemia and hypokalemia, which cannot be corrected without magnesium therapy. In addition, rhabdomyolysis was detected in animals, but it has not been reported in living related donor renal transplant recipients. In this case report, a living related donor renal transplant recipient who suffered from hypomagnesemia and mild rhabdomyolysis due to CsA therapy will be described and discussed.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cyclosporine / adverse effects*
  • Cyclosporine / therapeutic use
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation*
  • Living Donors
  • Magnesium / blood*
  • Magnesium Sulfate / therapeutic use
  • Male
  • Rhabdomyolysis / chemically induced*

Substances

  • Immunosuppressive Agents
  • Magnesium Sulfate
  • Cyclosporine
  • Magnesium